186 related articles for article (PubMed ID: 38024530)
1. Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S; Wang H
Drug Des Devel Ther; 2023; 17():3429-3437. PubMed ID: 38024530
[TBL] [Abstract][Full Text] [Related]
2. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
3. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F
Thorac Cancer; 2019 Mar; 10(3):551-556. PubMed ID: 30666799
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
7. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
8. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
[TBL] [Abstract][Full Text] [Related]
10. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
[No Abstract] [Full Text] [Related]
11. Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma.
Jiang B; Li J; Chen J; Xiang X; Xiong J; Deng J
Thorac Cancer; 2020 Feb; 11(2):461-464. PubMed ID: 31891239
[TBL] [Abstract][Full Text] [Related]
12. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
13. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib as a molecular targeted therapy for tumors.
Gao Y; Liu P; Shi R
Oncol Lett; 2020 Aug; 20(2):1001-1014. PubMed ID: 32724339
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
Zhong RB; Xu JL; Lou YQ; Chu TQ; Zhong H; Han BH
Ann Palliat Med; 2020 Jul; 9(4):1681-1687. PubMed ID: 32575999
[TBL] [Abstract][Full Text] [Related]
16. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
17. Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.
Zhen H; Tian J; Li G; Zhao P; Zhang Y; Che J; Cao B
BMC Cancer; 2023 Mar; 23(1):207. PubMed ID: 36870981
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
Wang W; Shao L; Xu Y; Song Z; Lou G; Zhang Y; Chen M
BMC Pulm Med; 2022 May; 22(1):179. PubMed ID: 35524294
[TBL] [Abstract][Full Text] [Related]
19. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
Lu J; Zhong H; Chu T; Zhang X; Li R; Sun J; Zhong R; Yang Y; Alam MS; Lou Y; Xu J; Zhang Y; Wu J; Li X; Zhao X; Li K; Lu L; Han B
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578392
[TBL] [Abstract][Full Text] [Related]
20. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.
Li N; Wu T; Hong YG; Guo YZ; Cheng YF; Ma YJ; Bie LY; Cui DH; Gao XH; Tan BX; Li BS; Luo SX; Wang JS
BMC Med; 2022 Dec; 20(1):472. PubMed ID: 36482345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
